Groundbreaking new study on Parkinson’s disease

Brain scientists have revealed new insights into Parkinson’s disease that could pave the way to discovering a treatment.

Dr Taylor Stevenson and Dr Justin Rustenhoven have made a significant new discovery about Parkinson's disease. Photo: Rose Davis.
Dr Taylor Stevenson and Dr Justin Rustenhoven have made a significant new discovery about Parkinson's disease. Photo: Rose Davis.

Understandings of Parkinson’s disease have shifted dramatically through new research from the University of Auckland Centre for Brain Research.

Dr Justin Rustenhoven and Dr Taylor Stevenson have published a paper offering world-first evidence that a toxic protein builds up in protective tissues that surround the brain in people with Parkinson’s disease.

The findings open the possibility of developing drugs to treat Parkinson’s that don’t have to break through the blood-brain barrier that usually stops foreign substances entering the brain.

“We’re excited by what we found, because it would be much easier to treat tissues surrounding the brain, or the immune response to these toxic proteins, than it is to get drugs inside the brain,” says Rustenhoven.

The protein alpha-synuclein is known to drive the progression of Parkinson’s disease within the brain. It causes inflammation that kills brain cells, triggering the symptoms of Parkinson’s, which include tremors, slow movement and difficulty walking.

Now, Stevenson and Rustenhoven have shown that alpha-synuclein also accumulates in the meninges – the protective layer surrounding the brain.

The study revealed that alpha-synuclein triggers an immune response, which damages the brain’s major drainage system – the meningeal lymphatic system.

“Alpha-synuclein causes inflammation that essentially pokes holes in the brain’s drainage pipes.

“That means more and more harmful waste, including alpha-synuclein, builds up in tissues in and around the brain,” says Stevenson.

Dr Justin Rustenhoven says it could be easier to treat Parkinson's disease in tissue outside the brain. Photo: Rose Davis.
Dr Justin Rustenhoven says the findings are exciting, because it could be easier to treat Parkinson's disease in tissue outside the brain. Photo: Rose Davis.

For the past four years, the Neurological Foundation Human Brain Bank at the University of Auckland has been building one of the few libraries in the world of donated meningeal tissue.

Over the past three years, Rustenhoven and Stevenson have examined this tissue and lab models to uncover their findings.

The next step is to test whether new and existing drugs can target the meninges or the immune system to help restore the brain’s waste clearance systems.

“Currently, there are no drugs that slow the progression of Parkinson’s disease, so the goal is to find one,” says Rustenhoven.

Parkinson's is the fastest-growing brain disorder in the world and the second most common neurodegenerative condition, after Alzheimer's disease.

Problems with the brain’s waste clearance systems are found not only in Parkinson’s, but in many other degenerative brain diseases, including Alzheimer’s, says Stevenson.

“So understanding what’s happening in Parkinson’s disease could potentially help with understanding other brain diseases,” Stevenson says.

Both Rustenhoven and Stevenson have PhDs in pharmacology from the University of Auckland.

The duo’s strength arises from each having different specialist knowledge. Rustenhoven’s expertise is in the brain’s waste clearance systems, while Stevenson brings knowledge of Parkinson’s disease.

From 2017, Rustenhoven spent five years in the US studying the lymphatic system that drains waste from the brain. Professor Jonathan Kipnis, who discovered this system, was his post-doctoral supervisor.

Stevenson’s PhD research with Professor Maurice Curtis from the Centre for Brain Research showed alpha-synuclein builds up in the olfactory bulb in people with Parkinson’s disease. This means many people with Parkinson’s lose their sense of smell years before movement symptoms appear.

A Rutherford Discovery Fellowship and funding from Auckland Medical Research Foundation allowed Rustenhoven to launch his research in 2021, while Stevenson has won funding from the Neurological Foundation, Ian and Sue Parton, and the Marsden Fund.

An image showing alpha-synuclein in green and the lymphatic vessels that clear waste from the brain in purple.
An image showing alpha-synuclein in green and the lymphatic vessels that clear waste from the brain in purple.

Media contact

Rose Davis | Research communications adviser
M:
027 568 2715
E: rose.davis@auckland.ac.nz